Collaboration partners and funding sources

Slørdahl KS, Puco K, Falk RS, Dyvik I, Brabrand S, Niehusmann P, Steinskog ESS, Blix ES, Flobak Å, Oppedal IA, Meltzer S, Torkildsen CF, Blakstad H, Lindemann K, Smeland S, Amundsen A, Taskén K, Helland Å, InPred Consortium (2026)
Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial
Acta Oncol, 65, 90-96
DOI 10.2340/1651-226X.2026.45086, PubMed 41664938

Emblem KE, Ringstad G, Svensson SF, Vatnehol SAS, Storås TH, Vik-Mo EO, Heggebø LC, Brandal P, Eide PK (2025)
Intrathecal contrast-enhanced MRI reveals an alternative route for drug delivery and brain tumor visualization
Cancer Lett, 638, 218152
DOI 10.1016/j.canlet.2025.218152, PubMed 41276108

Furtner J, Berchtold L, Le Rhun E, Silvani A, Rudà R, Lombardi G, Sepúlveda-Sánchez JM, Brandal P, Bendszus M, Golfinopoulos V, Gorlia T, Sahm F, Wick W, Minniti G, Weller M, König F, Preusser M (2025)
Prognostic value of 1D, 2D, and volumetric tumor size increases in recurrent WHO grade 2 and 3 meningiomas: Radiological post-hoc analysis of the EORTC-BTG-1320 trial
Neurooncol Adv, 7 (1), vdaf152
DOI 10.1093/noajnl/vdaf152, PubMed 40735273